4536 N Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥339.23 |
| 52 Week High | JP¥0 |
| 52 Week Low | JP¥0 |
| Beta | 0.34 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4536 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.5% |
| 1Y | 0% | -18.0% | -3.1% |
Return vs Industry: 4536 N exceeded the MX Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: 4536 N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| 4536 N volatility | |
|---|---|
| 4536 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.2% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: 4536 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4536 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 4,315 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products, including Verkazia, which is used for the treatment of vernal keratoconjunctivitis; STN1008903, which is used for dry eye treatment; Eybelis for the treatment of glaucoma and ocular hypertension; Alesion, an anti-allergy ophthalmic solution; Diquas for the treatment for dry eye syndrome; and glaucoma products, such as Tapros, Tapcom, PRESERFLO MicroShunt, and ROCK inhibitor products. The company also developing various pharmaceutical products to treat glaucoma, such as STN1014000, which is in clinical preparation; STN1012600, which is in Phase II clinical trial; STN1011101, STN1013001, and STN1013900, which are in Phase III clinical trial; STN1011402, which is in Phase III clinical trial to treat allergies; STN1010904, which is in Phase II clinical trial to treat fuchs endothelial corneal dystrophy; STN1010905, which is in Phase II clinical trial to treat meibomian gland dysfunction; and STN1013600, which is in Phase I clinical trial to treat presbyopia.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| 4536 N fundamental statistics | |
|---|---|
| Market cap | Mex$57.74b |
| Earnings (TTM) | -Mex$1.85b |
| Revenue (TTM) | Mex$34.54b |
1.6x
P/S Ratio-30.8x
P/E RatioIs 4536 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4536 N income statement (TTM) | |
|---|---|
| Revenue | JP¥279.04b |
| Cost of Revenue | JP¥112.95b |
| Gross Profit | JP¥166.09b |
| Other Expenses | JP¥181.04b |
| Earnings | -JP¥14.95b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 03, 2023
| Earnings per share (EPS) | -40.07 |
| Gross Margin | 59.52% |
| Net Profit Margin | -5.36% |
| Debt/Equity Ratio | 0% |
How did 4536 N perform over the long term?
See historical performance and comparison